Nicht lieferbar
Family Support Network for Adolescent Cannabis Users - Services, U. S. Department of Health and
Schade – dieser Artikel ist leider ausverkauft. Sobald wir wissen, ob und wann der Artikel wieder verfügbar ist, informieren wir Sie an dieser Stelle.
  • Broschiertes Buch

Thus, substance-abusing adolescents experiencing inadequate family structure and functioning will be at a serious disadvantage with regard to recovery. Their recovery, however, is likely to be enhanced if family functioning can be improved. Deficits in family functioning may be related to dimensions of authority, roles, boundaries, communication, and routines. Parental authority may be eroded and roles confused; boundaries may be blurred or violated; communication may be dysfunctional and conflict laden; and family structure or routine may be lacking. Inadequate parenting skills or poor…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Thus, substance-abusing adolescents experiencing inadequate family structure and functioning will be at a serious disadvantage with regard to recovery. Their recovery, however, is likely to be enhanced if family functioning can be improved. Deficits in family functioning may be related to dimensions of authority, roles, boundaries, communication, and routines. Parental authority may be eroded and roles confused; boundaries may be blurred or violated; communication may be dysfunctional and conflict laden; and family structure or routine may be lacking. Inadequate parenting skills or poor understanding of family dynamics may also contribute to a chaotic or otherwise dysfunctional family context.
Autorenporträt
TIP 63 Update--- To ensure that the content of this TIP is as up to date and as useful to readers as possible, SAMHSA, in January 2020, revised certain areas of all five parts. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes included the following: . Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. . Updating the expanded list of other qualifying practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives). . Clarifying that buprenorphine is available in an extended-release injection formulation. . Adding information about the use of subdermal formulations of buprenorphine (i.e., Probuphine and Sublocade). . Adding information about possible clinical interactions between formulations of buprenorphine and naltrexone with various other medications and products. . Improving the language to make clear the importance of testing for HIV and hepatitis C. . Updating recommendations from the U.S. Preventive Services Task Force on performing drug screening for adults in primary care settings. . Removing or replacing broken hyperlinks to online resources.